vs

Side-by-side financial comparison of LendingClub Corp (LC) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

LendingClub Corp is the larger business by last-quarter revenue ($252.3M vs $151.7M, roughly 1.7× Tarsus Pharmaceuticals, Inc.). LendingClub Corp runs the higher net margin — 20.5% vs -5.5%, a 26.0% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 15.9%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 16.1%).

LendingClub Corporation is an American financial services company headquartered in San Francisco, California. It was the first peer-to-peer lender to register its offerings as securities with the Securities and Exchange Commission (SEC), and to offer loan trading on a secondary market. At its height, LendingClub was the world's largest peer-to-peer lending platform. The company reported that $15.98 billion in loans had been originated through its platform up to December 31, 2015.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

LC vs TARS — Head-to-Head

Bigger by revenue
LC
LC
1.7× larger
LC
$252.3M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+112.5% gap
TARS
128.4%
15.9%
LC
Higher net margin
LC
LC
26.0% more per $
LC
20.5%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
16.1%
LC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LC
LC
TARS
TARS
Revenue
$252.3M
$151.7M
Net Profit
$51.6M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
20.5%
-5.5%
Revenue YoY
15.9%
128.4%
Net Profit YoY
341.0%
63.8%
EPS (diluted)
$0.44
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LC
LC
TARS
TARS
Q1 26
$252.3M
Q4 25
$266.5M
$151.7M
Q3 25
$266.2M
$118.7M
Q2 25
$248.4M
$102.7M
Q1 25
$217.7M
$78.3M
Q4 24
$217.2M
$66.4M
Q3 24
$201.9M
$48.1M
Q2 24
$187.2M
$40.8M
Net Profit
LC
LC
TARS
TARS
Q1 26
$51.6M
Q4 25
$-8.4M
Q3 25
$44.3M
$-12.6M
Q2 25
$38.2M
$-20.3M
Q1 25
$11.7M
$-25.1M
Q4 24
$-23.1M
Q3 24
$14.5M
$-23.4M
Q2 24
$14.9M
$-33.3M
Operating Margin
LC
LC
TARS
TARS
Q1 26
Q4 25
18.8%
-5.3%
Q3 25
21.5%
-12.2%
Q2 25
21.7%
-21.6%
Q1 25
7.2%
-33.5%
Q4 24
5.1%
-36.8%
Q3 24
8.9%
-52.3%
Q2 24
10.4%
-81.6%
Net Margin
LC
LC
TARS
TARS
Q1 26
20.5%
Q4 25
-5.5%
Q3 25
16.6%
-10.6%
Q2 25
15.4%
-19.8%
Q1 25
5.4%
-32.1%
Q4 24
-34.8%
Q3 24
7.2%
-48.7%
Q2 24
8.0%
-81.6%
EPS (diluted)
LC
LC
TARS
TARS
Q1 26
$0.44
Q4 25
$0.36
$-0.17
Q3 25
$0.37
$-0.30
Q2 25
$0.33
$-0.48
Q1 25
$0.10
$-0.64
Q4 24
$0.08
$-0.57
Q3 24
$0.13
$-0.61
Q2 24
$0.13
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LC
LC
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$1.5B
$343.4M
Total Assets
$11.9B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LC
LC
TARS
TARS
Q1 26
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Total Debt
LC
LC
TARS
TARS
Q1 26
Q4 25
$0
$72.4M
Q3 25
$0
$72.3M
Q2 25
$0
$72.1M
Q1 25
$0
$72.0M
Q4 24
$0
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
LC
LC
TARS
TARS
Q1 26
$1.5B
Q4 25
$1.5B
$343.4M
Q3 25
$1.5B
$335.1M
Q2 25
$1.4B
$332.6M
Q1 25
$1.4B
$342.5M
Q4 24
$1.3B
$224.5M
Q3 24
$1.3B
$237.5M
Q2 24
$1.3B
$252.2M
Total Assets
LC
LC
TARS
TARS
Q1 26
$11.9B
Q4 25
$11.6B
$562.2M
Q3 25
$11.1B
$534.6M
Q2 25
$10.8B
$495.0M
Q1 25
$10.5B
$500.8M
Q4 24
$10.6B
$377.0M
Q3 24
$11.0B
$376.3M
Q2 24
$9.6B
$376.8M
Debt / Equity
LC
LC
TARS
TARS
Q1 26
Q4 25
0.00×
0.21×
Q3 25
0.00×
0.22×
Q2 25
0.00×
0.22×
Q1 25
0.00×
0.21×
Q4 24
0.00×
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LC
LC
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LC
LC
TARS
TARS
Q1 26
Q4 25
$-2.7B
$19.3M
Q3 25
$-770.8M
$18.3M
Q2 25
$-713.1M
$-29.4M
Q1 25
$-339.3M
$-20.7M
Q4 24
$-2.6B
$-22.2M
Q3 24
$-669.8M
$-8.7M
Q2 24
$-932.5M
$-14.4M
Free Cash Flow
LC
LC
TARS
TARS
Q1 26
Q4 25
$-2.9B
$13.0M
Q3 25
$-791.8M
$16.3M
Q2 25
$-803.8M
$-30.4M
Q1 25
$-352.3M
$-21.2M
Q4 24
$-2.7B
$-22.3M
Q3 24
$-682.3M
$-8.9M
Q2 24
$-945.3M
$-15.4M
FCF Margin
LC
LC
TARS
TARS
Q1 26
Q4 25
-1076.0%
8.6%
Q3 25
-297.4%
13.8%
Q2 25
-323.5%
-29.6%
Q1 25
-161.8%
-27.1%
Q4 24
-1237.8%
-33.5%
Q3 24
-338.0%
-18.6%
Q2 24
-504.9%
-37.8%
Capex Intensity
LC
LC
TARS
TARS
Q1 26
Q4 25
52.7%
4.2%
Q3 25
7.9%
1.6%
Q2 25
36.5%
1.0%
Q1 25
6.0%
0.8%
Q4 24
25.0%
0.1%
Q3 24
6.2%
0.6%
Q2 24
6.9%
2.5%
Cash Conversion
LC
LC
TARS
TARS
Q1 26
Q4 25
Q3 25
-17.41×
Q2 25
-18.68×
Q1 25
-29.07×
Q4 24
Q3 24
-46.33×
Q2 24
-62.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons